**Core Concept**
Chemotherapy-induced dose-limiting toxicity (DLT) refers to the adverse effects that prevent further dose escalation of a chemotherapeutic agent, thereby limiting its therapeutic efficacy. DLT can be due to various mechanisms, including direct DNA damage, disruption of cellular homeostasis, and impairment of organ function.

**Why the Correct Answer is Right**
The correct answer is related to the concept of myelosuppression, which is a common DLT of many chemotherapeutic agents. Myelosuppression is characterized by a decrease in the production of blood cells, including red blood cells, white blood cells, and platelets. This occurs due to the inhibition of bone marrow stem cells by chemotherapeutic agents, leading to anemia, leukopenia, and thrombocytopenia. Myelosuppression is a dose-limiting toxicity because it can lead to severe infections, bleeding, and anemia, thereby compromising the patient's quality of life and increasing the risk of complications.

**Why Each Wrong Option is Incorrect**
**Option A:** While gastrointestinal toxicity is a common side effect of chemotherapy, it is not typically a dose-limiting toxicity. Gastrointestinal toxicity can be managed with supportive care, and patients can often continue to receive chemotherapy despite these symptoms.
**Option B:** Hepatotoxicity is a potential side effect of certain chemotherapeutic agents, but it is not the most common dose-limiting toxicity. Hepatotoxicity can be managed with dose adjustments and supportive care, and patients can often continue to receive chemotherapy despite these symptoms.
**Option C:** Neurotoxicity is a potential side effect of certain chemotherapeutic agents, but it is not the most common dose-limiting toxicity. Neurotoxicity can be managed with dose adjustments and supportive care, and patients can often continue to receive chemotherapy despite these symptoms.

**Clinical Pearl / High-Yield Fact**
The most common chemotherapeutic agents that cause myelosuppression include cyclophosphamide, doxorubicin, bleomycin, and etoposide. These agents can cause a significant decrease in blood cell counts, making it essential to monitor patients closely for signs of myelosuppression.

**Correct Answer: C. Myelosuppression**